We do not recommend Casirivimab-Imdevimab for patients with mild COVID-19 and no risk factors for progression to severe disease (Strong recommendation)
Definition of mild illness:
Symptomatic (any acute COVID-19 related symptoms)
AND respiratory rate <24/min
WITHOUT pneumonia or hypoxia
We recommend Casirivimab-Imdevimab for use within 10 days of symptom onset in those with ≥ 1 risk factors for progression to severe disease with a non Omicron variant of COVID-19 (Conditional recommendation)
A conditional recommendation is one for which the panel is less confident about the balance between desirable and undesirable effects of the intervention, or other aspects, such as cost and feasibility.
Definition of mild illness:
Symptomatic (any acute COVID-19 related symptoms)
AND respiratory rate <24/min
WITHOUT pneumonia or hypoxia
Risk factors
1. Age >50 years
2. Obesity, defined as body mass index >30
3. Cardiovascular disease, including hypertension
4. Chronic lung disease, including asthma
5. Chronic metabolic disease, including diabetes
6. Chronic kidney disease, including those on dialysis